Sernova – Patentierte Zelltaschen mit Schutzschild gegen die Immunabwehr ! (Seite 839)
eröffnet am 24.06.15 16:59:24 von
neuester Beitrag 02.05.24 10:29:26 von
neuester Beitrag 02.05.24 10:29:26 von
Beiträge: 8.522
ID: 1.214.676
ID: 1.214.676
Aufrufe heute: 133
Gesamt: 1.077.284
Gesamt: 1.077.284
Aktive User: 4
ISIN: CA81732W1041 · WKN: A0LBCR · Symbol: PSH
0,2900
EUR
+0,52 %
+0,0015 EUR
Letzter Kurs 11:56:05 L&S Exchange
Neuigkeiten
30.04.24 · Shareribs Anzeige |
26.04.24 · Shareribs Anzeige |
25.04.24 · IRW Press |
24.04.24 · Shareribs Anzeige |
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,9700 | +324,79 | |
| 0,8100 | +305,00 | |
| 0,7400 | +36,63 | |
| 6,4000 | +24,51 | |
| 110,65 | +22,45 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0500 | -14,63 | |
| 0,5350 | -17,05 | |
| 0,5300 | -17,19 | |
| 10,120 | -34,75 | |
| 1,8819 | -55,93 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 50.783.676 von Popeye82 am 06.10.15 11:05:34Wie sehen eigentlich die nächsten Schritte bei Sernova aus?
Und wie sind diese zeitlich gesehen einzuordnen?
Und wie sind diese zeitlich gesehen einzuordnen?
die Katze lässt das mausen nicht
SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it recently initiated coverage of Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76.
The report is available here: SVA Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
With headquarters in London, Ontario, Sernova is a clinical stage medical company focused on developing disruptive platform technologies that use regenerative medicine to treat chronic diseases. Initially Sernova is developing medical technologies aimed at treating chronic metabolic diseases including Type 1 and Type 2 diabetes, blood disorders such as hemophilia, thyroid disease, and other diseases. We see several potential catalysts ahead for the company as it pursues a partner-based strategy for advancing its clinical development program - and ultimately commercialization – for the treatment of the approximately 30mn people worldwide who suffer from insulin-dependent diabetes.
"The company's patented Cell Pouch System(TM) is a novel, implantable medical device technology for delivering therapeutic cells in a safe and biologically appropriate environment," stated Ajay Tandon, CEO of SeeThruEquity. "We find the technology to be compelling, especially in light of the large market opportunity as 30 million people worldwide suffer from insulin-dependent diabetes. We are initiating coverage with a 12-month price target of CAD$0.76 per share."
Additional highlights from the report are as follows:
Cell Pouch System(TM) offers a novel approach to diabetes treatment
Sernova's Cell Pouch System(TM) is a subcutaneous implantable medical device technology that is designed for the transplantation of therapeutic cells, including donor, xenogeneic, or stem cell derived therapeutic cells to treat chronic diseases. The Cell Pouch System(TM) was custom designed to provide a natural environment for therapeutic cells, which then can produce missing proteins or hormones and release these therapeutics into the bloodstream. The Cell Pouch System™ can also provide local immune protection for the therapeutic cells and includes the full complement of technologies required to develop advanced cell-based treatments with applications in a number of chronic diseases involving the need for a missing protein, hormone or factor – suggesting that the technology has the potential for numerous indications beyond those enumerated by the company. Over the last six years Sernova has made considerable progress on its Cell Pouch System(TM) development program for insulin-dependent diabetes patients, with strong preclinical confirmation of safety and efficacy - as well as clinical success with human islets in brittle diabetics. Sernova recently secured access to a near-infinite supply of cells sourced from its licensed technology with University Health Network (UHN) of Toronto. We next expect the company to move forward to initiate a Phase 2 human trial using the Cell Pouch System(TM) to transplant therapeutic cells to insulin dependent diabetes patients.
Large market for diabetes therapeutics
Initially Sernova is targeting diabetes - a chronic disease that occurs when the pancreas does not produce enough insulin. Diabetes is a widespread and growing disease that affects approximately 387mn across the globe, a figure that is expected to rise to 592mn by 2035, according to the International Diabetes Federation (IDF). The cost of treating diabetes and its side effects represents a massive economic burden on healthcare, having been estimated at over $245Bn in North America alone. The initial target market for Sernova's Cell Pouch System(TM) is the 30mn insulin-dependent Type 1 and Type 2 diabetics worldwide. Although smaller in number, insulin dependent diabetics represent approximately 50% of the multi-billion dollar global market for diabetes. Following diabetes, Sernova's second clinical program for the Cell Pouch System(TM) is hemophilia, and the company also sees potential for the Cell Pouch System(TM) for treatment of thyroid disease, and other chronic diseases.
Initiate coverage with a price target of CAD $0.76
Our analysis indicates a fair value estimate of CAD $0.76 per share for Sernova. If achieved, the target represents potential upside of 145.2% from the recent price of CAD $0.31. We see Sernova as an intriguing speculative story in the healthcare sector with a potentially disruptive platform technology that is initially addressing the $420Bn+ global market for diabetes treatment, with several additional indications planned for the future.
Please review important disclosures on our website at www.seethruequity.com.
About Sernova Corp.
Sernova Corp. is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity
Read more at http://www.stockhouse.com/news/press-releases/2015/10/05/see…
NEW YORK, NY / ACCESSWIRE / October 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it recently initiated coverage of Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76.
The report is available here: SVA Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
With headquarters in London, Ontario, Sernova is a clinical stage medical company focused on developing disruptive platform technologies that use regenerative medicine to treat chronic diseases. Initially Sernova is developing medical technologies aimed at treating chronic metabolic diseases including Type 1 and Type 2 diabetes, blood disorders such as hemophilia, thyroid disease, and other diseases. We see several potential catalysts ahead for the company as it pursues a partner-based strategy for advancing its clinical development program - and ultimately commercialization – for the treatment of the approximately 30mn people worldwide who suffer from insulin-dependent diabetes.
"The company's patented Cell Pouch System(TM) is a novel, implantable medical device technology for delivering therapeutic cells in a safe and biologically appropriate environment," stated Ajay Tandon, CEO of SeeThruEquity. "We find the technology to be compelling, especially in light of the large market opportunity as 30 million people worldwide suffer from insulin-dependent diabetes. We are initiating coverage with a 12-month price target of CAD$0.76 per share."
Additional highlights from the report are as follows:
Cell Pouch System(TM) offers a novel approach to diabetes treatment
Sernova's Cell Pouch System(TM) is a subcutaneous implantable medical device technology that is designed for the transplantation of therapeutic cells, including donor, xenogeneic, or stem cell derived therapeutic cells to treat chronic diseases. The Cell Pouch System(TM) was custom designed to provide a natural environment for therapeutic cells, which then can produce missing proteins or hormones and release these therapeutics into the bloodstream. The Cell Pouch System™ can also provide local immune protection for the therapeutic cells and includes the full complement of technologies required to develop advanced cell-based treatments with applications in a number of chronic diseases involving the need for a missing protein, hormone or factor – suggesting that the technology has the potential for numerous indications beyond those enumerated by the company. Over the last six years Sernova has made considerable progress on its Cell Pouch System(TM) development program for insulin-dependent diabetes patients, with strong preclinical confirmation of safety and efficacy - as well as clinical success with human islets in brittle diabetics. Sernova recently secured access to a near-infinite supply of cells sourced from its licensed technology with University Health Network (UHN) of Toronto. We next expect the company to move forward to initiate a Phase 2 human trial using the Cell Pouch System(TM) to transplant therapeutic cells to insulin dependent diabetes patients.
Large market for diabetes therapeutics
Initially Sernova is targeting diabetes - a chronic disease that occurs when the pancreas does not produce enough insulin. Diabetes is a widespread and growing disease that affects approximately 387mn across the globe, a figure that is expected to rise to 592mn by 2035, according to the International Diabetes Federation (IDF). The cost of treating diabetes and its side effects represents a massive economic burden on healthcare, having been estimated at over $245Bn in North America alone. The initial target market for Sernova's Cell Pouch System(TM) is the 30mn insulin-dependent Type 1 and Type 2 diabetics worldwide. Although smaller in number, insulin dependent diabetics represent approximately 50% of the multi-billion dollar global market for diabetes. Following diabetes, Sernova's second clinical program for the Cell Pouch System(TM) is hemophilia, and the company also sees potential for the Cell Pouch System(TM) for treatment of thyroid disease, and other chronic diseases.
Initiate coverage with a price target of CAD $0.76
Our analysis indicates a fair value estimate of CAD $0.76 per share for Sernova. If achieved, the target represents potential upside of 145.2% from the recent price of CAD $0.31. We see Sernova as an intriguing speculative story in the healthcare sector with a potentially disruptive platform technology that is initially addressing the $420Bn+ global market for diabetes treatment, with several additional indications planned for the future.
Please review important disclosures on our website at www.seethruequity.com.
About Sernova Corp.
Sernova Corp. is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay Tandon
SeeThruEquity
info@seethruequity.com
SOURCE: SeeThruEquity
Read more at http://www.stockhouse.com/news/press-releases/2015/10/05/see…
http://web.tmxmoney.com/article.php?newsid=78475455&qm_symbo…
SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76
SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76
Trading Spotlight
Jeden Tag derselbe Mist hier.
Mit ein paar Stücken hochziehen und dann abladen.
Mit ein paar Stücken hochziehen und dann abladen.
Antwort auf Beitrag Nr.: 50.749.206 von techinvestor69 am 01.10.15 09:24:18Stimme weitestgehend zu. Indes habe ich in meinen fast 20 Jahren Börse gelernt, dass Werte mit viel Fantasie oftmals leider genau das bleiben: Fantasie. Ich habe z.B. einen nicht unwesentlichen Verlust mit Verisante (V.VRS) realisieren müssen, weil ich erkannt habe, dass es für diese bahnbrechende Technologie (Krebserkennung mit Lichtwellen) zu dem avisierten Preis des Geräts keinen Markt gibt. Ein anderes Beispiel ist Silex Systems, ein australisches Unternehmen, das Uran via Laser anreichern kann. Das Verfahren ist revolutionär, alles spricht dafür, doch bisher ist es nicht gelungen die Technologie zu kommerzialisieren. Ein weiteres Beispiel dieser Art ist Argex, ebenfalls ein kanadisches Unternehmen. Es hält eine neue Technologie zur Gewinnung von Titandioxid, das gewissermaßen überall eingesetzt wird (Farben, Zahnpaste, Papier etc.). Auch hier ist man trotz vieler Versprechen nicht an den Punkt gelangt, dass die Technologie in großem Stil zum Einsatz kommt. Ein weiteres Unternehmen ist Microvision, die Miniprojektoren herstellen. Hier scheint endlich die Wende erreicht zu sein. Man schau sich aber mal die Aktie im 15-Jahres-Chart an. Wer hier schon lange dabei ist, hat einfach nur katastrophal viel Geld verloren.
Alle diese Werte haben großes Potenzial, wenn die Technologie Früchte trägt und an den Markt kommt. Genauso wie bei Sernova. Nur kostet es meist Unsummen, bis dies geschieht. Unsummen, die durch exorbitante Verwässerung der Aktie generiert werden.
Daher muss man sehr genau schauen, ob und wie lange es dauert, bis ein Unternehmen sein Geschäftsmodell realisieren kann. Eine gute Technologie heißt nicht, dass es auch kommerziell ein Erfolg wird. Aber nur letzteres erlaubt nachhaltig steigende Aktienkurse.
M@trix
Alle diese Werte haben großes Potenzial, wenn die Technologie Früchte trägt und an den Markt kommt. Genauso wie bei Sernova. Nur kostet es meist Unsummen, bis dies geschieht. Unsummen, die durch exorbitante Verwässerung der Aktie generiert werden.
Daher muss man sehr genau schauen, ob und wie lange es dauert, bis ein Unternehmen sein Geschäftsmodell realisieren kann. Eine gute Technologie heißt nicht, dass es auch kommerziell ein Erfolg wird. Aber nur letzteres erlaubt nachhaltig steigende Aktienkurse.
M@trix
Jeder Investor sollte sich ein eigenes Bild von der jeweiligen Firma machen und niemandem blind hinterherlaufen.
Sernova hat POTENTIELL eine bahnbrechende Lösung für Diabetes. Die größte Diabetes-Stiftung der Welt unterstützt Sernova sicher nicht aus Spaß. Ich habe meine Meinung und meine Berechnungen für den Wert.
"wenn alles so toll wäre, würden die meisten Unternehmen nicht dort stehen wo sie stehen" - Schau Dir doch mal die kanadischen Indexe an und setze das in Verbindung mit kanadischen Smallcaps. Die meisten kanadischen Small Caps haben KEINEN institutionellen Support, weil schlicht zu klein. Und wie definierst Du eigentlich "gegen die Wand laufen"? Ich habe keinen meiner Werte pleite gehen sehen.
Die meisten Investoren haben einfach keine Geduld und sind nur auf das schnelle Geld aus. Nichts gegen schnelles Geld, aber in einigen Fällen muss man auch das big picture, wie zB bei Naturally Splendid oder Telesta, sehen.
Sernova hat POTENTIELL eine bahnbrechende Lösung für Diabetes. Die größte Diabetes-Stiftung der Welt unterstützt Sernova sicher nicht aus Spaß. Ich habe meine Meinung und meine Berechnungen für den Wert.
"wenn alles so toll wäre, würden die meisten Unternehmen nicht dort stehen wo sie stehen" - Schau Dir doch mal die kanadischen Indexe an und setze das in Verbindung mit kanadischen Smallcaps. Die meisten kanadischen Small Caps haben KEINEN institutionellen Support, weil schlicht zu klein. Und wie definierst Du eigentlich "gegen die Wand laufen"? Ich habe keinen meiner Werte pleite gehen sehen.
Die meisten Investoren haben einfach keine Geduld und sind nur auf das schnelle Geld aus. Nichts gegen schnelles Geld, aber in einigen Fällen muss man auch das big picture, wie zB bei Naturally Splendid oder Telesta, sehen.
Antwort auf Beitrag Nr.: 50.743.593 von techinvestor69 am 30.09.15 15:28:21Ich habe in letzter Zeit leider viel zu viele kanadische Buden gegen die Wand laufen sehen, da fällt es schwer auch nur annähernd an solche Kurse zu denken..wenn alles so toll wäre, würden die meisten Unternehmen nicht dort stehen wo sie stehen..bei Sirona ja ähnlich..ich bin mit einem kleinen Invest hier dabei und hoffe natürlich, dass du auch nur annähernd recht hast mit deinen Prognosen..
@Dennis - An der Heimatbörse werden jeden Tag ein paar 100.000 Stück gehandelt. Da ist durchaus Interesse vorhanden. Wenn die Deutschen die Story nicht verstehen, umso besser. Mir ehrlich gesagt auch egal. Hier werden "big bucks" verdient. Mit Dir oder ohne Dich. 
Durchsuchen
